A new US study that analyzed data from a large national survey has found a significant link between diets low in fiber and increased cardiometabolic risk, a cluster of risk factors that increases a person s chances of having diabetes, heart disease or stroke.
Samsung Electronics America Inc. announced today the U.S. commercial release of its first Digital Radiology (DR) system, the Samsung XGEO GC80. The Samsung XGEO GC80, which received 510(k) approval from the U.S. Food and Drug Administration earlier this year, represents Samsung’s entrance into the DR market with a premium system offering advanced imaging technology, award-winning* design and user-friendly workflows to meet the demands of the 21st century radiology departments.
Bristol-Myers Squibb Company (NYSE: BMY) ha anunciado los resultados de seguimiento a largo plazo (mediana de seguimiento de 20,3 meses) de la cohorte de cáncer de pulmón (n=129) de la fase de extensión de fase 1 de búsqueda de dosis (003) de nivolumab, un inhibidor experimental del punto de control inmunitario PD-1. Los resultados demostraron que la actividad se mantenía en pacientes con cáncer de pulmón no microcítico (CPNM) altamente pretratados. En concreto, se observaron unas tasas de supervivencia a un año y a dos años del 42% y 24% respectivamente en todas las cohortes de dosis. Estos datos, que se basan en estimaciones de Kaplan-Meier, se han presentado en el 15º Congreso Mundial sobre Cáncer de Pulmón (Abstract # MO18.03).
Madrid, noviembre de 2013.- Sanitas ha firmado el acuerdo por el que se convierte en Proveedor Médico Oficial de la Copa del Mundo de Baloncesto 2014 que se celebrará en nuestro país del 30 de agosto al 14 de septiembre de 2014.
Barcelona, noviembre de 2013. El equipo de Ginecología y Obstetricia liderado por el econocido especialista profesor Santiago Dexeus se ha incorporado al cuadro médico de Sanitas Hospitales en Cataluña. El equipo ya ha iniciado las consultas en el Milenium Centro Médico Iradier y desarrollará su actividad quirúrgica en el Hospital Sanitas CIMA de Barcelona.
En España, se registran 60.000 casos anuales de Tromboembolismo Pulmonar (TEP) que generan 50.000 ingresos hospitalarios El proyecto OSIRIS dará a conocer la incidencia de Hipertensión Pulmonar Postrombótica (HPTEC) tras dos años de un episodio de Tromboembolismo Pulmonar (TEP), para mejorar el diagnóstico y el tratamiento
On 2 October 2013, Biotronik announced the launch of the Passeo-35 0.035” OTW PTA balloon Line Extension and the Passeo-35 HP high pressure percutaneous transluminal angioplasty (PTA) balloon. The Passeo-35 0.035” OTW PTA balloon is now also available in lengths of up to 200mm and the Passeo-35 HP high pressure PTA balloon is designed for arteriovenous dialysis fistulae application.
Medtronic, Inc. (Minneapolis, MN) announced the presentation of 3-year data from the SYMPLICITY HTN-2 at the TCT 2013: Transcatheter Cardiovascular Therapeutics conference in San Francisco, California. SYMPLICITY HTN-2, a randomized, controlled clinical trial of renal denervation in patients with uncontrolled hypertension. These data demonstrate results consistent with data reported previously at 6, 12, and 24 months of follow-up.
On 2 October 2013, Biotronik announced the launch of the Passeo-35 0.035” OTW PTA balloon Line Extension and the Passeo-35 HP high pressure percutaneous transluminal angioplasty (PTA) balloon. The Passeo-35 0.035” OTW PTA balloon is now also available in lengths of up to 200mm and the Passeo-35 HP high pressure PTA balloon is designed for arteriovenous dialysis fistulae application.
New data presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco, USA, demonstrate an excellent safety profile for Boston Scientific’s renal denervation system.
Uncontrolled hypertension is not the same as resistant hypertension. Experts at the third UK Symposium on Renal Denervation (16 October, London, UK) urged physicians to universally apply ambulatory blood pressure monitoring in order to help distinguish between the two and work within a multidisciplinary team to suitably select patients before offering the minimally invasive catheter-based procedure.
Surefire Medical announced the launch of a new, enhanced infusion system—the Surefire Infusion System mT—designed to treat vessels as small as 2mm to 3.5mm in interventional direct-to-target embolization procedures.
St. Jude Medical, Inc. (St. Paul, MN) announced new results from the EnligHTN I study that confirm safe, rapid, and sustained reduction in blood pressure measurements at 18 months after treatment with the company’s EnligHTN multielectrode renal denervation system. Professor Stephen Worthley, MD, from St. Andrew’s Hospital in Adelaide, Australia, a primary investigator in the EnligHTN I trial, presented the findings at the TCT 2013: Transcatheter Cardiovascular Therapeutics conference in San Francisco, California.
Medtronic has announced that it has received investigational device exemption (IDE) approval from the FDA to conduct SYMPLICITY HTN-4—the first randomised trial to investigate renal denervation for the treatment of moderate uncontrolled hypertension in US patients.
On 29 October, Terumo Interventional Systems announced the launch of the 0.018” Glidewire Advantage peripheral guidewire during the 25th Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco, USA (27 October–1 November).
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos